Home Hemodialysis with the Tablo System: The First 1,000 Real-World Treatments

Michael Aragon, MD
Josh Schumacher

.Outset

BACKGROUND:

The Tablo® Hemodialysis System is an all in one, easy-to-learn device capable of achieving clearance goals in as little as three treatments per week. It features integrated water purification, on-demand dialysate production and two-way wireless data transmission.

Tablo obtained FDA clearance for Home Hemodialysis (HHD) in March 2020 based on a prospective, cross-over between in-center and at home dialysis trial (NCT02460263).

Tablo met all safety and effectiveness endpoints, reported high rates of treatment adherence and patient retention, with greatly reduced training time.

OBJECTIVE:

Report on the first 1,000 treatments performed on Tablo by patients at home in the real-world.

METHODS:

- Incident and prevalent patients currently performing in-center dialysis, PD, or HHD were initiated on Tablo.
- Patients underwent training by facility nurses prior to beginning treatments at home.
- Data on the first 1000 treatments was obtained wirelessly via Tablo's data platform, along with corresponding patient training data.

RESULTS:

- Average training time was 7.4 training days.
- Patient retention was 100% with no patients opting out of HHD with Tablo.
- Mean prescribed treatment time was 3.2 hours with a mean frequency of 3.7 treatments per week.
- Mean UF rate per treatment was 7.3 mL/kg/hr.
- Treatment adherence was 93%, with 95% of treatments completing within 10% of prescribed time.
- The mean number of clinically significant alarms per treatment was 1.0 (± 3.0), with an average time to resolution of 10.7 (± 18.5) seconds.

This data supports that Tablo is capable of successfully achieving clinical goals while reducing the overall patient burden often associated with HHD.

CONCLUSION:

Results from the Tablo IDE trial are reproducible in the real world at a frequency of 3-4 treatments/week.

Treatment Results

Variable	Treatment Data (Mean ± SD)
Patient Weight (kg)	89.8 ± 25.4
Actual Treatment Time (hrs)	3.2 ± 0.8
Actual UF Rate (mL/kg/hr)	7.3 ± 4.1

Prescribed HHD at 3.7 treatments/week

✔ 100% Retention Rate

✔ 95.4% Treatment Success

✔ 93.2% Treatment Adherence

Tablo is easy to use, with minimal burden on patients

✔ 27.4 hours over 7.9 sessions of Tablo Training

✔ 1.0 Alarm per Treatment

✔ 10.7 seconds to Alarm Resolution

Observed averages for first 20 patients and 1,000 treatments.

CONTACT FOR CORRESPONDENCE
Michael Aragon, MD • maragon@outsetmedical.com